PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14608078-5	2003	We examined the effect of folic acid supplementation for 6 wk and 12 mo (5 mg/d for 1 wk, 1 mg/d for 37 wk and 0.4 mg/d for the remaining 14 wk) on LOX-1 mRNA levels and on oxLDL-induced release of tumor necrosis factor alpha from peripheral blood mononuclear cells in hyperhomocysteinemic individuals.	Folic Acid	26-36	oxidized low density lipoprotein receptor 1	Homo sapiens	148-153	
14608078-8	2003	Folic acid treatment led to a normalization of homocysteine levels accompanied by a reduction in LOX-1 gene expression (P < 0.02) and in oxLDL-stimulated release of TNFalpha (P < 0.05).	Folic Acid	0-10	oxidized low density lipoprotein receptor 1	Homo sapiens	97-102	
14608078-9	2003	These novel findings suggest both that homocysteine exerts its atherogenic effect in part by elevating levels of LOX-1, thereby enhancing oxLDL-induced inflammatory responses, and most important, that folic acid supplementation may downregulate these responses.	Folic Acid	201-211	oxidized low density lipoprotein receptor 1	Homo sapiens	113-118